| Dr Nicholas Lyndon Wright, MD | |
|
1906 Belleview Ave Se, Roanoke, VA 24014-1838 | |
| (540) 981-7337 | |
| Not Available |
| Full Name | Dr Nicholas Lyndon Wright |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 7 Years |
| Location | 1906 Belleview Ave Se, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760903611 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Medical Center | Roanoke, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acv Inc | 3870633936 | 60 |
News Archive
An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Key to a child's successful education is an environment in which he or she can learn safely. According to a report released today by the C.S. Mott Children's Hospital National Poll on Children's Health, only 26 percent of parents would give their child's high school an "A" for preventing bullying and school violence, and 38 percent of parents would give their child's elementary or junior high an "A."
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Advanced Medical Isotope Corporation, a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that it has filed a de novo submission with the Food and Drug Administration for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act.
› Verified 2 days ago
| Entity Name | Acv Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881927259 PECOS PAC ID: 3870633936 Enrollment ID: O20091221000602 |
News Archive
An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Key to a child's successful education is an environment in which he or she can learn safely. According to a report released today by the C.S. Mott Children's Hospital National Poll on Children's Health, only 26 percent of parents would give their child's high school an "A" for preventing bullying and school violence, and 38 percent of parents would give their child's elementary or junior high an "A."
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Advanced Medical Isotope Corporation, a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that it has filed a de novo submission with the Food and Drug Administration for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas Lyndon Wright, MD 4659 Whipplewood Ct, Roanoke, VA 24018-7305 Ph: (813) 951-8926 | Dr Nicholas Lyndon Wright, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7337 |
News Archive
An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Key to a child's successful education is an environment in which he or she can learn safely. According to a report released today by the C.S. Mott Children's Hospital National Poll on Children's Health, only 26 percent of parents would give their child's high school an "A" for preventing bullying and school violence, and 38 percent of parents would give their child's elementary or junior high an "A."
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Advanced Medical Isotope Corporation, a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that it has filed a de novo submission with the Food and Drug Administration for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act.
› Verified 2 days ago
Dr. David S. Hunt, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Teodulo Remandaban, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Elizabeth H. Duckworth, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Charles K. Gadpaille, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. George Landon Smith, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 | |
Dr. Neil A. Macdonald, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Patrick Banner Robertson, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 |